Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4211-4215

  Yamamoto, Kazuyoshi ^a   Fujiwara, Yoshiyuki ^a   Nishida, Toshiro ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; DFP; Docetaxel; Gastric cancer; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; REMISSION INDUCTION; STOMACH NEOPLASMS; TAXOIDS;

EID: 71949119289     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, Hiratsuka M, Tsujinaka T, Kinoshita T, Arai K, Yamamura Y and Okajima K; Japan Clinical Oncology Group: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 359: 453-462, 2008.
3. MacDonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM and Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001. (Pubitemid 34936653)
4. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S and Chua YJ, MAGIC Trial Participants: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
5. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R and Mansfield PF: Phase II study of taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 4: 269-274, 1988.
6. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, Akazawa S, Kitajima M, Kanamaru R and Taguchi T: An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 21: 416-419, 1998. (Pubitemid 28366916)
7. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA and Benson AB III: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87-93, 1996. (Pubitemid 27019943)
8. Taguchi T: An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract. Jpn J Cancer Chemother 21: 2431-2437, 1994. (Pubitemid 24347727)
9. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, Yoshino M, Taguchi T and Ogawa N: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Jpn J Cancer Chemother pp. 1033-1038, 1994.
10. Taguchi T, Tsukagoshi S, Furue H, Niitani H and Noda K: Phase I clinical study of oxaliplatin. Jpn J Cancer Chemother 25: 1899-907, 1998.
11. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720, 1998. (Pubitemid 28474225)
12. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J and Fumoleau P: Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264-1270, 2003. (Pubitemid 36579198)
13. Uedo N, Nakajima H, Ishihara R, Takiuchi H, Goto M, Fujitani K, Hirao M, Tsujinaka T, Imano M, Furukawa H, Tsukuma H and Taguchi T: Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 73: 65-71, 2007.
14. Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H and Taguchi T: Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology 74: 37-41, 2008. (Pubitemid 351915008)
15. Kawabata R, Fujiwara Y, Doki Y, Fujita J, Tsukahara Y, Yamasaki M, Miyata H, Takiguchi S and Monden M: Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. Oncology 72: 219-225, 2007. (Pubitemid 351161614)
16. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J and Nishiyama M: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006. (Pubitemid 43917349)
17. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yamanaka K and Orita H: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
18. Liu C, Sun Q, Hang X, Zhong B and Wang D: Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs 19: 825-831, 2008.
19. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P and Ajani JA: Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229: 303-308, 1999. (Pubitemid 30191763)
20. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR and Fink U: Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 6: 159-167, 2003. (Pubitemid 37221566)
21. Yamao T, Ohta K, Ohyama S, Ishihara S, Chin K, Maruyama M, Takahashi T and Nakajima T: A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases. Jpn J Clin Oncol 34: 225-261, 2004. (Pubitemid 43102886)
22. Ott K, Lordick F, Herrmann K, Krause BJ, Schumacher C and Siewert JR: The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer 11: 1-9, 2008.
23. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J and Hirabayashi N: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A) Jpn J Cancer Chemother 25: 1915-1924, 1998.
24. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, Hirabayashi N and Taguchi T and Furue H: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B). Jpn J Cancer Chemother 26: 487-496, 1999.
25. Hejna M, Raderer M, Zacherl J, Ba-Ssalamah A, Püspök A, Schmidinger M, Pluschnig U, Brodowicz T and Zielinski CC: Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease: results of the Central European Cooperative Oncology Group Study ESGAS. Anticancer Drugs 19: 535-539, 2008. (Pubitemid 351559607)
26. Ajani JA: Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. Cancer 113(5): 945-955, 2008.
27. Cutsem EV, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E and Russe NK: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006. (Pubitemid 46631401)
28. Chung YS, Yamashita Y, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato Y, Shirasaka T and Sowa M: Continuous infusion of 5-fluorouracil and low-dose cisplatin infusion for the treatment of advanced recurrent gastric adenocarcinoma. Cancer 80: 1-7, 1997. (Pubitemid 27270913)
29. Kim R, Murakami S, Ohi Y, Inoue H, Yoshida K and Toge T: A phase II trial of low-dose administration of 5-fluorouracil and cisplatin in patients with advanced recurrent gastric cancer. Int J Oncol 15: 921-926, 1999.
30. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
32. Japanese Gastric Cancer Association, Japanese Classification of Gastric Carcinoma-2nd English version. Gastric Cancer 1(1): 10-24, 1998.
33. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Jones RG, Widmer L, Seymour M and Braud F: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25: 3217-3223, 2007. (Pubitemid 47325604)